StockNews.com Lowers Esperion Therapeutics (NASDAQ:ESPR) to Hold

StockNews.com lowered shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a buy rating to a hold rating in a research note released on Wednesday morning. ESPR has been the topic of several other research reports. Needham & Company LLC lowered their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set […]

Leave a Reply

Your email address will not be published.

Previous post Nuvation Bio (NYSE:NUVB) Receives Outperform Rating from Wedbush
Next post Stryker (NYSE:SYK) Given Overweight Rating at Piper Sandler